DHT-UN.TO
Full HouseDRI Healthcare Trust · Healthcare · Canada · $743M cap · $484K/day traded
CAD 19.47 -0.3% · close 12 Nov · scored 13 Nov
Full House: Strong business, sensible price, and the market agrees.
After its 4 Nov results, analysts raised next year's EPS estimate 3.8%.
As of 13 Nov 2026, the MoatMap Score for DRI Healthcare Trust (DHT-UN.TO) is 93/100, ranked against 25,000+ stocks in 38 markets (Quality 56, Value 68, Momentum 76, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT DRI HEALTHCARE TRUST
Read
DRI Healthcare Trust focuses on managing and growing a portfolio of pharmaceutical royalties. It owns a portfolio of 18 royalties derived from the sale of 14 various pharmaceutical products that focuses on eight therapeutic areas.
FINANCIAL SUMMARY (CAD)
Reported in USD
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 103.9M | 126.5M | 192.0M | 214.3M | 27.3% | 290.2M | 214.0M | 246.6M | 6.3% |
| EPS (CAD) | 0.39 | 2.78 | -0.08 | -1.27 | 612.6% | 1.51 | — | — | — |
| Shares | 37.8M | 56.4M | 56.3M | 55.1M | +45.7% | — | — | — | — |
| Debt | 332.0M | 192.5M | 460.3M | 515.0M | 15.8% | 871.1M | — | — | — |
| Equity | 504.6M | 740.5M | 757.0M | 600.6M | 6.0% | — | — | — | — |
| Op CF | 100.7M | 103.1M | 212.8M | 153.6M | 15.1% | 246.4M | — | — | — |
| Inv CF | -355.8M | -173.8M | -401.6M | -112.1M | — | — | — | — | — |
| Fin CF | 222.6M | 106.0M | 152.7M | -33.2M | — | — | — | — | — |
Above its 200-day average and 2% below its 52-week high.
Calmer than 80% of stocks we rank over the past year (volatility 27% a year).
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor: It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend (this stock): It is near its 52-week high and above its 200-day average.
- No clear trend: None of the above: no recent deep fall and no steady climb.
- No read yet: Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DHT-UN.TO are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| DHT-UN.TO | DRI Healthcare Trust(you) | $743M | 93 |
| GUD.TO | Knight Therapeutics Inc. | $814M | 82 |
| XLY.TO | Auxly Cannabis Group Inc. | $246M | 96 |
| BHC | Bausch Health Companies Inc. | $2.4B | 96 |
| CPH.TO | Cipher Pharmaceuticals Inc. | $243M | 84 |
| CRON.TO | Cronos Group Inc. | $1.2B | 69 |
| RX.V | BioSyent Inc. | $136M | 94 |
| LOVE.TO | Cannara Biotech Inc. | $142M | 89 |
| MDP.TO | Medexus Pharmaceuticals Inc. | $111M | 84 |
| ACB.TO | Aurora Cannabis Inc. | $247M | 55 |
Peer medians: ROE -31.6% · P/E 19.5x · Gross margin 50.7%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.